Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 30, 2021 09:00 ET | Source: Oncotelic Therapeutics, Inc.

ONCOTELIC THERAPEUTICS, INC. (FORMERLY MATEON THERAPEUTICS, INC.) NAME AND SYMBOL CHANGE.

AGOURA HILLS, Calif., March 30, 2021 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc. (“Oncotelic” or the “Company”) (OTCQB:OTLC) (f/k/a Mateon Therapeutics, Inc.) announced today that the Financial...
March 08, 2021 07:00 ET | Source: Mateon Therapeutics, Inc.

MATEON’S UPDATE ON C001 - GLOBAL STUDY FOR OT-101 AGAINST COVID-19

PART 1 AND 2 SENTINEL PATIENTS COMPLETED TREATMENT THE FIRST COHORT OF 18 PART 1 PATIENTS COMPLETED TREATMENT. AGOURA HILLS, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Mateon Therapeutics,...
November 30, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

DEVELOPMENT UPDATE FOR ARTIVEDA™/ARTISHIELD™ AGAINST COVID-19

--75% IMPROVEMENT BY DAY 2 ON ARTIVEDA™ AGOURA HILLS, California, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics, Inc. (OTCQB: MATN) (“Mateon”), a leading developer of TGF-β therapeutics...
September 21, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

OT-101 PRESENTATION AT PHARMA FORUM 2020

AGOURA HILLS, Calif., Sept. 21, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics “Mateon” (OTC.QB: MATN), a leading developer of TGF-β therapeutics for oncology and COVID-19, announced today that on...
June 23, 2020 07:00 ET | Source: Mateon Therapeutics, Inc.

Mateon Therapeutics Selects IQVIA for its Randomized, Controlled, Multi-Center Clinical Study to Test OT-101 as a Treatment for COVID-19 Patients

AGOURA HILLS, Calif., June 23, 2020 (GLOBE NEWSWIRE) -- Mateon Therapeutics (OTCQB: MATN), a leading developer of TGF-β therapeutics, has selected IQVIA to manage C001, a Phase 2 randomized,...
January 22, 2019 09:15 ET | Source: Oncotelic Inc

Oncotelic Inc. Announces Appointment of Fatih Uckun MD PhD to Chief Medical Officer

AGOURA HILLS, Calif, Jan. 22, 2019 (GLOBE NEWSWIRE) -- Oncotelic Inc. (“Oncotelic), a privately held cancer immunotherapy company dedicated to the discovery and development of in situ cancer...